nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—esophageal cancer	0.867	1	CbGaD
Nadolol—Slurred speech—Cisplatin—esophageal cancer	0.00409	0.0375	CcSEcCtD
Nadolol—Arterial thrombosis—Methotrexate—esophageal cancer	0.00373	0.0342	CcSEcCtD
Nadolol—Swelling face—Capecitabine—esophageal cancer	0.00283	0.026	CcSEcCtD
Nadolol—Peripheral coldness—Capecitabine—esophageal cancer	0.00283	0.026	CcSEcCtD
Nadolol—Hypertriglyceridaemia—Capecitabine—esophageal cancer	0.00235	0.0215	CcSEcCtD
Nadolol—Respiratory distress—Capecitabine—esophageal cancer	0.00212	0.0195	CcSEcCtD
Nadolol—Blood triglycerides increased—Capecitabine—esophageal cancer	0.00206	0.0189	CcSEcCtD
Nadolol—Dysarthria—Cisplatin—esophageal cancer	0.00193	0.0177	CcSEcCtD
Nadolol—Pain—Carboplatin—esophageal cancer	0.0019	0.0174	CcSEcCtD
Nadolol—Throat sore—Capecitabine—esophageal cancer	0.00187	0.0172	CcSEcCtD
Nadolol—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00185	0.017	CcSEcCtD
Nadolol—Body temperature increased—Carboplatin—esophageal cancer	0.00176	0.0161	CcSEcCtD
Nadolol—Fluid retention—Cisplatin—esophageal cancer	0.00174	0.0159	CcSEcCtD
Nadolol—Extrasystoles—Capecitabine—esophageal cancer	0.0016	0.0147	CcSEcCtD
Nadolol—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00149	0.0137	CcSEcCtD
Nadolol—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00148	0.0136	CcSEcCtD
Nadolol—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00146	0.0134	CcSEcCtD
Nadolol—Nasal congestion—Cisplatin—esophageal cancer	0.00146	0.0134	CcSEcCtD
Nadolol—Dysarthria—Capecitabine—esophageal cancer	0.00143	0.0131	CcSEcCtD
Nadolol—Amnesia—Cisplatin—esophageal cancer	0.00141	0.013	CcSEcCtD
Nadolol—Fluid retention—Capecitabine—esophageal cancer	0.00128	0.0117	CcSEcCtD
Nadolol—Irritability—Cisplatin—esophageal cancer	0.00127	0.0116	CcSEcCtD
Nadolol—Dry eye—Capecitabine—esophageal cancer	0.00125	0.0114	CcSEcCtD
Nadolol—Sleep disorder—Capecitabine—esophageal cancer	0.00113	0.0104	CcSEcCtD
Nadolol—Abdominal discomfort—Cisplatin—esophageal cancer	0.0011	0.0101	CcSEcCtD
Nadolol—Dysarthria—Methotrexate—esophageal cancer	0.00106	0.00973	CcSEcCtD
Nadolol—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00106	0.00973	CcSEcCtD
Nadolol—Libido decreased—Capecitabine—esophageal cancer	0.00106	0.00968	CcSEcCtD
Nadolol—Amnesia—Capecitabine—esophageal cancer	0.00104	0.00955	CcSEcCtD
Nadolol—Cardiac failure—Capecitabine—esophageal cancer	0.001	0.0092	CcSEcCtD
Nadolol—Lethargy—Capecitabine—esophageal cancer	0.000999	0.00916	CcSEcCtD
Nadolol—Conjunctivitis—Cisplatin—esophageal cancer	0.000995	0.00912	CcSEcCtD
Nadolol—Diplopia—Capecitabine—esophageal cancer	0.000979	0.00897	CcSEcCtD
Nadolol—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000971	0.0089	CcSEcCtD
Nadolol—Bradycardia—Cisplatin—esophageal cancer	0.000936	0.00857	CcSEcCtD
Nadolol—Irritability—Capecitabine—esophageal cancer	0.000935	0.00857	CcSEcCtD
Nadolol—Mood swings—Capecitabine—esophageal cancer	0.000928	0.0085	CcSEcCtD
Nadolol—Dry skin—Capecitabine—esophageal cancer	0.000898	0.00823	CcSEcCtD
Nadolol—Pulmonary oedema—Methotrexate—esophageal cancer	0.000894	0.00819	CcSEcCtD
Nadolol—Visual impairment—Cisplatin—esophageal cancer	0.000886	0.00812	CcSEcCtD
Nadolol—Gastritis—Capecitabine—esophageal cancer	0.000867	0.00794	CcSEcCtD
Nadolol—Tinnitus—Cisplatin—esophageal cancer	0.000857	0.00785	CcSEcCtD
Nadolol—Abdominal distension—Capecitabine—esophageal cancer	0.000852	0.00781	CcSEcCtD
Nadolol—Bronchospasm—Capecitabine—esophageal cancer	0.000833	0.00763	CcSEcCtD
Nadolol—Alopecia—Cisplatin—esophageal cancer	0.000812	0.00744	CcSEcCtD
Nadolol—Abdominal discomfort—Capecitabine—esophageal cancer	0.000811	0.00744	CcSEcCtD
Nadolol—Flatulence—Cisplatin—esophageal cancer	0.000788	0.00722	CcSEcCtD
Nadolol—Weight increased—Capecitabine—esophageal cancer	0.00077	0.00706	CcSEcCtD
Nadolol—Visual disturbance—Methotrexate—esophageal cancer	0.000769	0.00705	CcSEcCtD
Nadolol—Vision blurred—Cisplatin—esophageal cancer	0.000754	0.00691	CcSEcCtD
Nadolol—Depression—Capecitabine—esophageal cancer	0.000752	0.0069	CcSEcCtD
Nadolol—Lethargy—Methotrexate—esophageal cancer	0.000744	0.00682	CcSEcCtD
Nadolol—Conjunctivitis—Capecitabine—esophageal cancer	0.000734	0.00672	CcSEcCtD
Nadolol—Agranulocytosis—Capecitabine—esophageal cancer	0.000704	0.00645	CcSEcCtD
Nadolol—Irritability—Methotrexate—esophageal cancer	0.000696	0.00638	CcSEcCtD
Nadolol—Mood swings—Methotrexate—esophageal cancer	0.000691	0.00633	CcSEcCtD
Nadolol—Bradycardia—Capecitabine—esophageal cancer	0.00069	0.00632	CcSEcCtD
Nadolol—Oedema—Cisplatin—esophageal cancer	0.000653	0.00598	CcSEcCtD
Nadolol—Visual impairment—Capecitabine—esophageal cancer	0.000653	0.00598	CcSEcCtD
Nadolol—Tinnitus—Capecitabine—esophageal cancer	0.000632	0.00579	CcSEcCtD
Nadolol—Hyperhidrosis—Cisplatin—esophageal cancer	0.000631	0.00578	CcSEcCtD
Nadolol—Anorexia—Cisplatin—esophageal cancer	0.000622	0.0057	CcSEcCtD
Nadolol—Hypotension—Cisplatin—esophageal cancer	0.00061	0.00559	CcSEcCtD
Nadolol—Abdominal discomfort—Methotrexate—esophageal cancer	0.000604	0.00554	CcSEcCtD
Nadolol—Alopecia—Capecitabine—esophageal cancer	0.000599	0.00549	CcSEcCtD
Nadolol—Paraesthesia—Cisplatin—esophageal cancer	0.000586	0.00537	CcSEcCtD
Nadolol—Dyspnoea—Cisplatin—esophageal cancer	0.000582	0.00533	CcSEcCtD
Nadolol—Flatulence—Capecitabine—esophageal cancer	0.000581	0.00533	CcSEcCtD
Nadolol—Erectile dysfunction—Methotrexate—esophageal cancer	0.00058	0.00532	CcSEcCtD
Nadolol—Decreased appetite—Cisplatin—esophageal cancer	0.000568	0.0052	CcSEcCtD
Nadolol—Depression—Methotrexate—esophageal cancer	0.00056	0.00513	CcSEcCtD
Nadolol—Pain—Cisplatin—esophageal cancer	0.000558	0.00512	CcSEcCtD
Nadolol—Vision blurred—Capecitabine—esophageal cancer	0.000556	0.00509	CcSEcCtD
Nadolol—Conjunctivitis—Methotrexate—esophageal cancer	0.000546	0.005	CcSEcCtD
Nadolol—Sweating—Methotrexate—esophageal cancer	0.000539	0.00494	CcSEcCtD
Nadolol—Syncope—Capecitabine—esophageal cancer	0.000529	0.00485	CcSEcCtD
Nadolol—Agranulocytosis—Methotrexate—esophageal cancer	0.000524	0.0048	CcSEcCtD
Nadolol—Loss of consciousness—Capecitabine—esophageal cancer	0.000518	0.00475	CcSEcCtD
Nadolol—Body temperature increased—Cisplatin—esophageal cancer	0.000516	0.00473	CcSEcCtD
Nadolol—Cough—Capecitabine—esophageal cancer	0.000515	0.00472	CcSEcCtD
Nadolol—Hypertension—Capecitabine—esophageal cancer	0.000509	0.00467	CcSEcCtD
Nadolol—Chest pain—Capecitabine—esophageal cancer	0.000502	0.0046	CcSEcCtD
Nadolol—Dry mouth—Capecitabine—esophageal cancer	0.000491	0.0045	CcSEcCtD
Nadolol—Visual impairment—Methotrexate—esophageal cancer	0.000486	0.00445	CcSEcCtD
Nadolol—Oedema—Capecitabine—esophageal cancer	0.000481	0.00441	CcSEcCtD
Nadolol—Shock—Capecitabine—esophageal cancer	0.000474	0.00434	CcSEcCtD
Nadolol—Tinnitus—Methotrexate—esophageal cancer	0.00047	0.00431	CcSEcCtD
Nadolol—Asthenia—Cisplatin—esophageal cancer	0.000468	0.00429	CcSEcCtD
Nadolol—Hyperhidrosis—Capecitabine—esophageal cancer	0.000465	0.00426	CcSEcCtD
Nadolol—Anorexia—Capecitabine—esophageal cancer	0.000459	0.0042	CcSEcCtD
Nadolol—Hypotension—Capecitabine—esophageal cancer	0.00045	0.00412	CcSEcCtD
Nadolol—Diarrhoea—Cisplatin—esophageal cancer	0.000447	0.00409	CcSEcCtD
Nadolol—Alopecia—Methotrexate—esophageal cancer	0.000446	0.00408	CcSEcCtD
Nadolol—Insomnia—Capecitabine—esophageal cancer	0.000435	0.00399	CcSEcCtD
Nadolol—Paraesthesia—Capecitabine—esophageal cancer	0.000432	0.00396	CcSEcCtD
Nadolol—Dyspnoea—Capecitabine—esophageal cancer	0.000429	0.00393	CcSEcCtD
Nadolol—Dyspepsia—Capecitabine—esophageal cancer	0.000424	0.00388	CcSEcCtD
Nadolol—Decreased appetite—Capecitabine—esophageal cancer	0.000418	0.00383	CcSEcCtD
Nadolol—Vomiting—Cisplatin—esophageal cancer	0.000415	0.0038	CcSEcCtD
Nadolol—Fatigue—Capecitabine—esophageal cancer	0.000415	0.0038	CcSEcCtD
Nadolol—Vision blurred—Methotrexate—esophageal cancer	0.000414	0.00379	CcSEcCtD
Nadolol—Rash—Cisplatin—esophageal cancer	0.000412	0.00377	CcSEcCtD
Nadolol—Pain—Capecitabine—esophageal cancer	0.000412	0.00377	CcSEcCtD
Nadolol—Constipation—Capecitabine—esophageal cancer	0.000412	0.00377	CcSEcCtD
Nadolol—Dermatitis—Cisplatin—esophageal cancer	0.000411	0.00377	CcSEcCtD
Nadolol—Nausea—Cisplatin—esophageal cancer	0.000388	0.00355	CcSEcCtD
Nadolol—Cough—Methotrexate—esophageal cancer	0.000383	0.00351	CcSEcCtD
Nadolol—Body temperature increased—Capecitabine—esophageal cancer	0.00038	0.00349	CcSEcCtD
Nadolol—Chest pain—Methotrexate—esophageal cancer	0.000374	0.00343	CcSEcCtD
Nadolol—Hyperhidrosis—Methotrexate—esophageal cancer	0.000346	0.00317	CcSEcCtD
Nadolol—Asthenia—Capecitabine—esophageal cancer	0.000345	0.00316	CcSEcCtD
Nadolol—Anorexia—Methotrexate—esophageal cancer	0.000342	0.00313	CcSEcCtD
Nadolol—Pruritus—Capecitabine—esophageal cancer	0.000341	0.00312	CcSEcCtD
Nadolol—Hypotension—Methotrexate—esophageal cancer	0.000335	0.00307	CcSEcCtD
Nadolol—Diarrhoea—Capecitabine—esophageal cancer	0.000329	0.00302	CcSEcCtD
Nadolol—Insomnia—Methotrexate—esophageal cancer	0.000324	0.00297	CcSEcCtD
Nadolol—Paraesthesia—Methotrexate—esophageal cancer	0.000322	0.00295	CcSEcCtD
Nadolol—Dyspnoea—Methotrexate—esophageal cancer	0.000319	0.00293	CcSEcCtD
Nadolol—Dizziness—Capecitabine—esophageal cancer	0.000318	0.00292	CcSEcCtD
Nadolol—Dyspepsia—Methotrexate—esophageal cancer	0.000315	0.00289	CcSEcCtD
Nadolol—Decreased appetite—Methotrexate—esophageal cancer	0.000311	0.00285	CcSEcCtD
Nadolol—Fatigue—Methotrexate—esophageal cancer	0.000309	0.00283	CcSEcCtD
Nadolol—Pain—Methotrexate—esophageal cancer	0.000306	0.00281	CcSEcCtD
Nadolol—Vomiting—Capecitabine—esophageal cancer	0.000306	0.0028	CcSEcCtD
Nadolol—Rash—Capecitabine—esophageal cancer	0.000303	0.00278	CcSEcCtD
Nadolol—Dermatitis—Capecitabine—esophageal cancer	0.000303	0.00278	CcSEcCtD
Nadolol—Nausea—Capecitabine—esophageal cancer	0.000286	0.00262	CcSEcCtD
Nadolol—Body temperature increased—Methotrexate—esophageal cancer	0.000283	0.0026	CcSEcCtD
Nadolol—Asthenia—Methotrexate—esophageal cancer	0.000257	0.00236	CcSEcCtD
Nadolol—Pruritus—Methotrexate—esophageal cancer	0.000253	0.00232	CcSEcCtD
Nadolol—Diarrhoea—Methotrexate—esophageal cancer	0.000245	0.00225	CcSEcCtD
Nadolol—Dizziness—Methotrexate—esophageal cancer	0.000237	0.00217	CcSEcCtD
Nadolol—Vomiting—Methotrexate—esophageal cancer	0.000228	0.00209	CcSEcCtD
Nadolol—Rash—Methotrexate—esophageal cancer	0.000226	0.00207	CcSEcCtD
Nadolol—Dermatitis—Methotrexate—esophageal cancer	0.000226	0.00207	CcSEcCtD
Nadolol—Nausea—Methotrexate—esophageal cancer	0.000213	0.00195	CcSEcCtD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	8.12e-05	0.00339	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	8.08e-05	0.00337	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	7.97e-05	0.00332	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	7.9e-05	0.00329	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KMT2D—esophageal cancer	7.89e-05	0.00329	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	7.87e-05	0.00328	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADCYAP1—esophageal cancer	7.78e-05	0.00324	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PDE4D—esophageal cancer	7.73e-05	0.00322	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—GNG7—esophageal cancer	7.72e-05	0.00322	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	7.7e-05	0.00321	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKAP13—esophageal cancer	7.67e-05	0.0032	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—ADCYAP1—esophageal cancer	7.61e-05	0.00317	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—GNG7—esophageal cancer	7.55e-05	0.00315	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—GNG7—esophageal cancer	7.35e-05	0.00306	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	7.16e-05	0.00298	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADCYAP1—esophageal cancer	7.07e-05	0.00295	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADCYAP1—esophageal cancer	7.04e-05	0.00293	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PDE4D—esophageal cancer	7.02e-05	0.00293	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ADCYAP1—esophageal cancer	6.91e-05	0.00288	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL2—esophageal cancer	6.8e-05	0.00284	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—GNG7—esophageal cancer	6.68e-05	0.00278	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL2—esophageal cancer	6.65e-05	0.00277	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GDI2—esophageal cancer	6.48e-05	0.0027	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL2—esophageal cancer	6.48e-05	0.0027	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—WWOX—esophageal cancer	6.43e-05	0.00268	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	6.41e-05	0.00267	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GDI2—esophageal cancer	6.34e-05	0.00264	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—ANXA1—esophageal cancer	6.32e-05	0.00264	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—CASP8—esophageal cancer	6.23e-05	0.0026	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—ANXA1—esophageal cancer	6.19e-05	0.00258	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—SST—esophageal cancer	6.15e-05	0.00256	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FKBP1A—esophageal cancer	6.12e-05	0.00255	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—ANXA1—esophageal cancer	6.02e-05	0.00251	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—SST—esophageal cancer	6.02e-05	0.00251	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—GHRL—esophageal cancer	6e-05	0.0025	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—WIF1—esophageal cancer	5.98e-05	0.00249	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL2—esophageal cancer	5.88e-05	0.00245	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—GHRL—esophageal cancer	5.86e-05	0.00244	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	5.86e-05	0.00244	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—SST—esophageal cancer	5.86e-05	0.00244	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—GHRL—esophageal cancer	5.71e-05	0.00238	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	5.58e-05	0.00232	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	5.54e-05	0.00231	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CSNK1A1—esophageal cancer	5.52e-05	0.0023	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—ANXA1—esophageal cancer	5.47e-05	0.00228	CbGpPWpGaD
Nadolol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	5.39e-05	0.00225	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—SST—esophageal cancer	5.32e-05	0.00222	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	5.21e-05	0.00217	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—GHRL—esophageal cancer	5.18e-05	0.00216	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PFN1—esophageal cancer	5.16e-05	0.00215	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKAP13—esophageal cancer	5.02e-05	0.00209	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	4.94e-05	0.00206	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKAP13—esophageal cancer	4.91e-05	0.00205	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	4.87e-05	0.00203	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	4.73e-05	0.00197	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	4.71e-05	0.00196	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KMT2D—esophageal cancer	4.68e-05	0.00195	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ELMO1—esophageal cancer	4.64e-05	0.00193	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PDE4D—esophageal cancer	4.59e-05	0.00191	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KMT2D—esophageal cancer	4.58e-05	0.00191	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	4.58e-05	0.00191	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKAP13—esophageal cancer	4.56e-05	0.0019	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKAP13—esophageal cancer	4.53e-05	0.00189	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	4.52e-05	0.00188	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	4.52e-05	0.00188	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PDE4D—esophageal cancer	4.49e-05	0.00187	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	4.46e-05	0.00186	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—GNG7—esophageal cancer	4.36e-05	0.00182	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	4.33e-05	0.0018	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	4.27e-05	0.00178	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HIST1H2BM—esophageal cancer	4.18e-05	0.00174	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADCYAP1—esophageal cancer	4.18e-05	0.00174	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PDE4D—esophageal cancer	4.17e-05	0.00174	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PDE4D—esophageal cancer	4.15e-05	0.00173	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	4.08e-05	0.0017	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	4.08e-05	0.0017	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	3.96e-05	0.00165	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GNG7—esophageal cancer	3.94e-05	0.00164	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	3.88e-05	0.00162	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	3.84e-05	0.0016	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—WWOX—esophageal cancer	3.82e-05	0.00159	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	3.76e-05	0.00157	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	3.74e-05	0.00156	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—XIAP—esophageal cancer	3.7e-05	0.00154	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	3.63e-05	0.00151	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	3.57e-05	0.00149	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	3.55e-05	0.00148	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—WIF1—esophageal cancer	3.55e-05	0.00148	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	3.5e-05	0.00146	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CTNNA1—esophageal cancer	3.49e-05	0.00146	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	3.49e-05	0.00146	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—SST—esophageal cancer	3.48e-05	0.00145	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL2—esophageal cancer	3.47e-05	0.00145	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	3.47e-05	0.00145	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	3.42e-05	0.00143	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	3.42e-05	0.00142	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	3.4e-05	0.00142	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	3.39e-05	0.00141	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	3.31e-05	0.00138	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	3.28e-05	0.00137	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PSME1—esophageal cancer	3.25e-05	0.00135	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PSME2—esophageal cancer	3.25e-05	0.00135	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	3.25e-05	0.00135	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ANXA1—esophageal cancer	3.23e-05	0.00135	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	3.21e-05	0.00134	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	3.17e-05	0.00132	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—SST—esophageal cancer	3.16e-05	0.00132	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SST—esophageal cancer	3.14e-05	0.00131	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	3.11e-05	0.0013	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—SST—esophageal cancer	3.09e-05	0.00129	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	3.08e-05	0.00128	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	3.07e-05	0.00128	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PFN1—esophageal cancer	3.06e-05	0.00128	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOTCH3—esophageal cancer	3.06e-05	0.00128	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GHRL—esophageal cancer	3.06e-05	0.00128	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	3.06e-05	0.00127	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC52A3—esophageal cancer	3.05e-05	0.00127	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—BLVRB—esophageal cancer	3.05e-05	0.00127	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FBXW7—esophageal cancer	3.01e-05	0.00126	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	3.01e-05	0.00125	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	3e-05	0.00125	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	2.75e-05	0.00115	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOTCH2—esophageal cancer	2.75e-05	0.00114	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	2.69e-05	0.00112	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	2.69e-05	0.00112	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	2.64e-05	0.0011	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	2.63e-05	0.0011	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC10A2—esophageal cancer	2.6e-05	0.00108	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CA1—esophageal cancer	2.6e-05	0.00108	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.56e-05	0.00107	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.5e-05	0.00104	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	2.48e-05	0.00104	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	2.46e-05	0.00103	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFBR2—esophageal cancer	2.44e-05	0.00102	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	2.43e-05	0.00101	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	2.41e-05	0.001	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CA2—esophageal cancer	2.37e-05	0.00099	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GNG7—esophageal cancer	2.34e-05	0.000976	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SMAD4—esophageal cancer	2.31e-05	0.000961	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	2.29e-05	0.000955	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.26e-05	0.000943	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ADH7—esophageal cancer	2.21e-05	0.00092	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PLCE1—esophageal cancer	2.21e-05	0.00092	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—XIAP—esophageal cancer	2.19e-05	0.000914	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.19e-05	0.000913	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	2.15e-05	0.000894	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.08e-05	0.000868	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	2.07e-05	0.000865	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	2.06e-05	0.00086	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	2.03e-05	0.000846	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	2.02e-05	0.000841	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ADH1B—esophageal cancer	1.94e-05	0.000807	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PSME1—esophageal cancer	1.93e-05	0.000803	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PSME2—esophageal cancer	1.93e-05	0.000803	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	1.92e-05	0.000799	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.89e-05	0.000789	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HIF1A—esophageal cancer	1.89e-05	0.000787	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	1.88e-05	0.000786	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	1.88e-05	0.000786	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	1.88e-05	0.000782	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SST—esophageal cancer	1.87e-05	0.000777	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TYMP—esophageal cancer	1.85e-05	0.000771	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SST—esophageal cancer	1.82e-05	0.000761	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GHRL—esophageal cancer	1.82e-05	0.000758	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	1.82e-05	0.000758	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.82e-05	0.000757	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KDR—esophageal cancer	1.8e-05	0.000752	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.8e-05	0.00075	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	1.79e-05	0.000745	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	1.78e-05	0.000741	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	1.78e-05	0.000741	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.78e-05	0.00074	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALOX15—esophageal cancer	1.75e-05	0.000731	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	1.75e-05	0.000729	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOTCH1—esophageal cancer	1.7e-05	0.000709	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TPI1—esophageal cancer	1.67e-05	0.000697	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTO1—esophageal cancer	1.67e-05	0.000697	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	1.63e-05	0.00068	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALDOB—esophageal cancer	1.6e-05	0.000669	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	1.59e-05	0.000665	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GAPDH—esophageal cancer	1.54e-05	0.000644	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CREBBP—esophageal cancer	1.54e-05	0.000643	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.54e-05	0.000642	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CRABP1—esophageal cancer	1.53e-05	0.000638	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—esophageal cancer	1.51e-05	0.000631	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.49e-05	0.000621	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNG7—esophageal cancer	1.46e-05	0.000607	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—esophageal cancer	1.45e-05	0.000603	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	1.45e-05	0.000603	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	1.41e-05	0.00059	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOS3—esophageal cancer	1.38e-05	0.000575	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	1.37e-05	0.000571	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALDH2—esophageal cancer	1.36e-05	0.000568	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	1.34e-05	0.000558	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—esophageal cancer	1.31e-05	0.000548	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTT1—esophageal cancer	1.3e-05	0.000541	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ERBB2—esophageal cancer	1.29e-05	0.000538	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.28e-05	0.000534	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS1—esophageal cancer	1.22e-05	0.000507	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ENO1—esophageal cancer	1.22e-05	0.000507	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.21e-05	0.000506	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PSME1—esophageal cancer	1.2e-05	0.000499	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PSME2—esophageal cancer	1.2e-05	0.000499	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCND1—esophageal cancer	1.14e-05	0.000475	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	1.12e-05	0.000467	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1A—esophageal cancer	1.1e-05	0.00046	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	1.1e-05	0.000457	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KDR—esophageal cancer	1.07e-05	0.000447	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EP300—esophageal cancer	1.05e-05	0.000438	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KDR—esophageal cancer	1.05e-05	0.000437	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.03e-05	0.000431	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	1.01e-05	0.000421	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	9.87e-06	0.000411	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP19A1—esophageal cancer	9.72e-06	0.000405	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	9.15e-06	0.000381	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—esophageal cancer	9.15e-06	0.000381	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	8.99e-06	0.000375	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	8.95e-06	0.000373	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—esophageal cancer	8.95e-06	0.000373	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMOX1—esophageal cancer	8.87e-06	0.00037	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	8.79e-06	0.000367	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.59e-06	0.000358	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	8.41e-06	0.00035	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	8.19e-06	0.000341	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	8.01e-06	0.000334	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	7.8e-06	0.000325	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—esophageal cancer	7.77e-06	0.000324	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	7.66e-06	0.000319	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	7.63e-06	0.000318	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—esophageal cancer	7.51e-06	0.000313	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	7.5e-06	0.000312	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	6.77e-06	0.000282	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	6.62e-06	0.000276	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	6.55e-06	0.000273	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	6.41e-06	0.000267	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EP300—esophageal cancer	6.23e-06	0.00026	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EP300—esophageal cancer	6.1e-06	0.000254	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CREBBP—esophageal cancer	5.69e-06	0.000237	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—esophageal cancer	5.43e-06	0.000226	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—esophageal cancer	5.31e-06	0.000221	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	5.31e-06	0.000221	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	5.2e-06	0.000217	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NOS3—esophageal cancer	5.09e-06	0.000212	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—esophageal cancer	4.66e-06	0.000194	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	4.61e-06	0.000192	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	4.51e-06	0.000188	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—esophageal cancer	4.46e-06	0.000186	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—esophageal cancer	4.36e-06	0.000182	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—EP300—esophageal cancer	3.87e-06	0.000161	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.87e-06	0.000119	CbGpPWpGaD
